Minnesota FOIA #P009840501

Minnesota Partnership for Biotechnology – Lead Optimization of a Novel Epigenetic Inhibitor Series for Alcoholic Hepa...

This purchase order from the Twin Cities (Minnesota) government agency awarded Mayo Clinic a contract for the lead optimization of a novel epigenetic inhibitor series aimed at treating alcoholic hepatitis. The order, dated March 26, 2022, involves a single transaction with an obligated amount of $482,390. The vendor, Mayo Clinic, is located in Minneapolis, MN, USA. The procurement appears to be a multi-year research or development project, with the contract specifically for the Minnesota Partnership for Biotechnology. The award emphasizes biomedical research and drug development, with Mayo Clinic as the primary recipient. The order was issued by the Twin Cities government, which is categorized as a local government entity.

Description

Minnesota Partnership for Biotechnology – Lead Optimization of a Novel Epigenetic Inhibitor Series for Alcoholic Hepatitis Therapy.